Imatinib treatment of lymphangiomatosis (generalized lymphatic anomaly)

16Citations
Citations of this article
10Readers
Mendeley users who have this article in their library.

Abstract

Lymphangiomatosis (eg, generalized lymphatic anomaly) is an abnormal proliferation of lymphatic endothelial cells. It is often a childhood disease, but it may present in adulthood by infiltrating organs and cause obstruction, bleeding, or disruption of lymphatic flow. Pulmonary involvement may be mild or cause diffuse interstitial lung disease, airway obstruction, hemoptysis, chylothorax, chylopericardium, and culminate in respiratory failure. Treatment has been limited to surgical resection or drainage procedures because there is no accepted effective systemic therapy. This report presents a patient with lymphangiomatosis and life-threatening hemoptysis in whom positive immunostaining for c-KIT suggested upregulation of tyrosine kinase and whose disease was controlled with imatinib.

Cite

CITATION STYLE

APA

Libby, L. J., Narula, N., Fernandes, H., Gruden, J. F., Wolf, D. J., & Libby, D. M. (2016). Imatinib treatment of lymphangiomatosis (generalized lymphatic anomaly). JNCCN Journal of the National Comprehensive Cancer Network, 14(4), 383–386. https://doi.org/10.6004/jnccn.2016.0045

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free